SP 100030

Drug Profile

SP 100030

Latest Information Update: 05 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Signal Research Division
  • Class Anti-inflammatories
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Immunosuppression; Pulmonary fibrosis

Most Recent Events

  • 29 Sep 2004 Preclinical trials in Pulmonary fibrosis in Japan (unspecified route)
  • 29 Sep 2004 Preclinical trials in Pulmonary fibrosis in USA (unspecified route)
  • 29 Sep 2004 Data presented at the 14th Annual Congress of the European Respiratory Society (ERS-2004) have been added to the Respiratory Tract Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top